PRCT

Procept Biorobotics Corp

PRCT, USA

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

https://www.procept-biorobotics.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRCT
stock
PRCT

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: Healthcare Robotics with a 61.91% Upside Potential DirectorsTalk Interviews

Read more →
PRCT
stock
PRCT

Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$50.7273

Analyst Picks

Strong Buy

6

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.48

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-5.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.19 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-11.40 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.35

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 94.79% of the total shares of Procept Biorobotics Corp

1.

FMR Inc

(14.0191%)

since

2025/06/30

2.

Vanguard Group Inc

(9.4329%)

since

2025/06/30

3.

BlackRock Inc

(7.5639%)

since

2025/06/30

4.

Fidelity Growth Compy Commingled Pl S

(4.0186%)

since

2025/07/31

5.

AllianceBernstein L.P.

(3.8767%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.9434%)

since

2025/07/31

8.

T. Rowe Price Investment Management,Inc.

(2.7461%)

since

2025/06/30

9.

Fidelity Growth Company Fund

(2.7187%)

since

2025/07/31

10.

T. Rowe Price Associates, Inc.

(2.377%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.3346%)

since

2025/06/30

12.

Vanguard Small Cap Index

(2.293%)

since

2025/07/31

13.

State Street Corp

(2.2811%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(2.2754%)

since

2025/08/31

15.

Loomis, Sayles & Company LP

(2.1053%)

since

2025/06/30

16.

Champlain Investment Partners, LLC

(1.9244%)

since

2025/06/30

17.

Artisan Partners Limited Partnership

(1.7727%)

since

2025/06/30

18.

Baillie Gifford & Co Limited.

(1.5752%)

since

2025/06/30

19.

Fidelity Select Medical Tech and Devcs

(1.5458%)

since

2025/07/31

20.

AXA SA

(1.5287%)

since

2025/06/30

21.

Champlain Small Company Fund, LLC

(1.4574%)

since

2025/08/31

22.

BNP Paribas Investment Partners SA

(1.4095%)

since

2025/06/30

23.

JPMorgan Chase & Co

(1.375%)

since

2025/06/30

24.

Vanguard Small Cap Growth Index Inv

(1.2949%)

since

2025/07/31

25.

Mackenzie Investments

(1.2737%)

since

2025/06/30

26.

Fidelity Select Health Care

(1.2402%)

since

2025/07/31

27.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

(1.2361%)

since

2025/06/30

28.

T. Rowe Price Small-Cap Stock

(1.1879%)

since

2025/07/31

29.

Bank of America Corp

(1.1246%)

since

2025/06/30

30.

Global X Robotics & Artfcl Intllgnc ETF

(1.1155%)

since

2025/08/29

31.

Wellington Management Company LLP

(1.1058%)

since

2025/06/30

32.

AB Small Cap Growth A

(1.1029%)

since

2025/07/31

33.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0683%)

since

2025/07/31

34.

T. Rowe Price US Small-Cap Core Equity

(1.0539%)

since

2025/06/30

35.

T. Rowe Price Health Sciences

(1.0199%)

since

2025/07/31

36.

Canada Life US Small-Mid Cap Growth F

(0.9593%)

since

2025/06/30

37.

Fidelity Small Cap Index

(0.948%)

since

2025/06/30

38.

Fidelity Growth Company K6

(0.8872%)

since

2025/07/31

39.

Fidelity Small Cap Growth

(0.8787%)

since

2025/06/30

40.

Eventide Healthcare & Life Sciences I

(0.842%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2674

Latest Release

Date

2025-09-30

EPS Actual

-0.38

EPS Estimate

-0.41

EPS Difference

0.03

Surprise Percent

7.3171%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.